Physician profile
Sunitha A Ghanta
NPI 1194935155
$10,466.83
in general payments reported to CMS, 2019-2025
42 companies · $2,024 in 2025
The $2,024 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $930 · 2020: $726 · 2021: $1,198 · 2022: $1,775 · 2023: $1,528 · 2024: $2,285 · 2025: $2,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,792 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,792.27 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,234.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,713.53 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,119.20 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $807.04 | 2020-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $736.76 | 2022-2025 | Caplyta |
| Glaxosmithkline, LLC. | $437.70 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $404.62 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $399.45 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Amarin Pharma, INC. | $385.63 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $262.53 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $260.39 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $232.18 | 2023-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $208.02 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $165.18 | 2023-2025 | |
| Antares Pharma, INC. | $122.15 | 2022-2025 | Xyosted, Tlando, Nocdurna |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $104.76 | 2024-2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $86.24 | 2025 | |
| Abbott Laboratories | $65.65 | 2021-2024 | Freestyle Libre 3 |
| Amgen INC. | $64.78 | 2019-2025 | Otezla, Repatha, Repatha |
| Allergan, INC. | $59.24 | 2020 | |
| Bausch Health US, LLC | $57.16 | 2023-2025 | Aplenzin |
| Idorsia Pharmaceuticals US INC | $55.03 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $51.12 | 2019-2020 | |
| Ibsa Pharma INC. | $45.96 | 2024 | Tirosint, Licart |
| Ardelyx, INC. | $41.61 | 2024 | Ibsrela |
| Kowa Pharmaceuticals America, INC. | $38.86 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $38.56 | 2025 | Fanapt |
| Lundbeck LLC | $37.61 | 2025 | Rexulti |
| Chiesi USA, INC. | $23.94 | 2024 | Filsuvez |
| Ironshore Pharmaceuticals INC. | $20.63 | 2019 | |
| Dexcom, INC. | $19.15 | 2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $17.49 | 2024 | Gemtesa |
| Scynexis, INC. | $17.24 | 2022 | |
| Pbg Puerto Rico LLC | $16.74 | 2021 | |
| Genentech USA, INC. | $16.18 | 2021 | |
| Almatica Pharma LLC | $15.00 | 2022 | |
| Halozyme INC | $15.00 | 2023 | |
| Sanofi Pasteur INC. | $14.81 | 2019 | |
| Adlon Therapeutics L.P. | $14.14 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.13 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.61 | 2019 | |
| Exact Sciences Corporation | $13.18 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunitha Ghanta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.